New Targets in the Therapeutic Landscape for
Moderate-to-Severe Atopic Dermatitis (AD): What
Does Managed Care Need to Know?

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 10, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals Alliance

Description:
Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin and have shown the ability to manage the disease in the short term, but have had troubles with long term efficacy. Thankfully advances in the understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. Fortunately, several new treatments, including novel monoclonal antibodies or targeted therapies, have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.

Upon Completion of this activity, participants will be able to:

  • Examine the impact of inadequately treated moderate-to-severe atopic dermatitis on physical and mental health, quality of life and work productivity

  • Design individualized treatment plans for adults with moderate-to-severe AD based on current guideline recommendations, safety and efficacy of new and emerging treatment options, comorbidities and patient quality of life

  • Discuss the mechanisms of action, efficacy and safety data for new biologic therapies and which moderate-to-severe AD patients are likely to benefit

  • Assess key points and strategies that managed care professionals need to know about new therapies in moderate-to-severe AD

  • Create and implement strategies to overcome barriers for monitoring treatment outcomes and promoting adherence among adults with moderate-to-severe AD
     

Faculty: Robert Sidbury, MD, MPH
Division Chief, Dermatology
Seattle Children’s Hospital
Professor
University of Washington School of Medicine

Disclosure:

Dr. Sidbury receives research support from Regeneron and financial support for CME programs from educational grants. He previously served on an advisory board for Pfizer and previously acted as a consultant to Roche. His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals Alliance

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue